Navigation Links
Third Circuit Rules in Mylan's Favor Regarding Paroxetine Hydrochloride Extended-Release Tablets, Sending Mylan's Breach of Contract Claim Against GSK to Trial
Date:7/23/2013

PITTSBURGH, July 23, 2013 /PRNewswire/ -- Mylan Inc. (NASDAQ: MYL) today announced that the Third Circuit Court of Appeals has reversed a summary judgment ruling dismissing Mylan's claim for breach of contract against GlaxoSmithKline relating to Paroxetine Hydrochloride Extended-release (ER) Tablets. The court ordered that Mylan's contract claim proceed to trial in U.S. District Court for the District of New Jersey. Mylan had filed suit against GSK claiming that GSK's agreement to supply Apotex with Paroxetine Hydrochloride ER violated Mylan's settlement and license agreement with GSK.  Mylan is seeking money damages and an order permanently enjoining GSK from supplying Apotex with Paroxetine Hydrochloride ER. The company is pleased with the court's decision and the case will proceed to trial.

This press release includes statements that constitute "forward-looking statements," including with regard to litigation and sales of the product. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com


'/>"/>
SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rochester Medical Announces Third Quarter 2013 Earnings Conference Call Tuesday, July 30, 2013
2. Hill-Rom Announces Preliminary Fiscal 2013 Third Quarter Results and Search for New CFO; Adjusted Earnings Per Share Expected to be in Line with Guidance
3. Span-America Medical Systems to Release Third Quarter Results on July 31, 2013
4. Aviir Secures Third $10 Million Financing Tranche To Fund Expanded Sales Of New Heart Risk Test
5. New Research: Nationwide Report Shows Prescribed Drugs Not Detected in More Than One-Third of Pain Patient Samples
6. Lilly Declares Third-Quarter 2013 Dividend
7. Cantel Medical Reports EPS of $0.33 vs. $0.30 on 8% Sales Increase for Third Quarter Ended April 30, 2013
8. Cantel Medical Corp. To Hold Conference Call To Discuss Results for Its Third Quarter Ended April 30, 2013
9. Hill-Rom Increases Third Quarter 2013 Dividend
10. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year
11. TPI Reports Third Quarter Fiscal Year 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)...  MiMedx Group, Inc. (NASDAQ: MDXG ), the ... other birth tissues, human skin and bone, and patent-protected ... products and therapies, announced today that it will present ... in New York , NY.  Parker ... Senken , Chief Financial Officer and Chris Cashman ...
(Date:2/11/2016)... Feb. 11, 2016 Wearable posture tracker, ALEX , has taken Kickstarter by storm, crowdfunding ... seven days left to go, ALEX is said to be delivered to backers starting May of this ... ... ... Created by NAMU, a ...
(Date:2/11/2016)... INDIANAPOLIS , Feb. 11, 2016  Attending ... but for those with type 1 diabetes, the journey ... juggle class schedules, assignments and campus activities, they also ... diabetes. On top of that, many are living away ... Scholars Foundation (Foundation) Lilly Diabetes Tomorrow,s Leaders Scholarship ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... Greenfield ... charity program created to assist the people of their local community. The agency ... organizations and community leaders. Their hope is to bring awareness to important local ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... Village Family Practice , will be presenting at the 2016 HIMSS Annual Conference ... Nev. , During his session, “ Coding for Care: Using Data Analytics ...
(Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases the ... of DataPoint’s team dedication and commitment to the SharePoint ecosystem. A panel ... list. The panel’s goal is to recognize and promote technology entrepreneurship. , The ...
(Date:2/11/2016)... Washington, D.C. (PRWEB) , ... February 11, 2016 ... ... will be exhibiting at the American Academy of Dermatology Annual Meeting at ... Hidrex USA's goal is to raise awareness for both the condition of hyperhidrosis ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... become more actively engaged in health and wellness best practices in the past ... riding this trend. February is American Heart Month, which acts as an exceptional ...
Breaking Medicine News(10 mins):